The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas - 29/05/22
ABSTRACT |
PROCLIPI is the PROgnostic Cutaneous Lymphoma International Prognostic Index Study with the main aim to produce a prognostic index in mycosis fungoides (MF) and Sezary syndrome (SS). The study prospectively collects clinical, haematological, pathological, imaging, treatment with responses, quality of life and survival data using careful predefined datasets. Patients are subject to a central review to confirm diagnosis. PROCLIPI opened in 2015 and recruitment has been strong with to date 1916 patients recruited from 52 Centres from 19 countries across 6 continents.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 51 - N° 1
Artículo 104123- mars 2022 Regresar al número
Artículo precedente
- New developments in skin-directed treatments of cutaneous T-cell lymphoma
- Iris Amitay-Laish, Emmilia Hodak
- Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification
- Rein Willemze
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?